Esmya is a pharmaceutical medication primarily used in the management of uterine fibroids, which are non-cancerous growths of the uterus. Its active ingredient is ulipristal acetate, a selective progesterone receptor modulator (SPRM) that works by altering the action of progesterone, a hormone involved in the menstrual cycle and pregnancy. Esmya is particularly prescribed to premenopausal women for the treatment of moderate to severe symptoms of uterine fibroids, such as heavy menstrual bleeding and pain. By targeting the hormonal pathways, Esmya helps to reduce the size of fibroids and alleviate symptoms, offering an alternative to surgical options for some patients. However, its use has been subject to regulatory review due to concerns over liver injury, and it is important for patients to be closely monitored while on this medication.